CHRISTOPHER KROEGER, M.D., M.B.A.
Chief Executive Officer
Dr. Kroeger joined OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals, leading teams that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to his position at Cardioxyl, he led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.
Dr. Kroeger earned his B.A. from Harvard University, his M.D. from Stanford University School of Medicine and did his Residency in General Surgery at the Brigham and Women’s Hospital, an affiliate of Harvard Medical School. He also holds his M.B.A. from Harvard Business School. Dr. Kroeger currently serves on the Board of Directors of CardioFocus, Inc. and Cantex Pharmaceuticals, Inc.
JAMES D. LUTERMAN, PH.D.
EVP, Research and Development
Dr. Luterman has been with OvaScience since January 2014 and most recently served as Senior Vice President, Research & Development. He brings over 20 years of industry experience to the Company. Prior to OvaScience, Dr. Luterman was an Early Development Team Leader at Shire Human Genetic Therapies, where he led the matrix management of Development Candidates from nomination through IND. Prior to Shire, he was a Program Leader at CombinationRx where he guided program strategy for the company’s flagship product and lead the development team through multiple clinical trials. Earlier in his career he worked at Biogen and Decision Resources Group, where he developed commercial analysis and recommendations for early stage clinical development programs.
Dr. Luterman holds a B.A. in Biology and Psychology from Bucknell University and a Ph.D. in Behavioral and Neural Sciences from Rutgers University. Dr. Luterman was a postdoctoral fellow at Mount Sinai School of Medicine in New York.
LOUIS S. VILLALBA
SVP, Corporate Development
Mr. Villalba has been with OvaScience since November 2015 and most recently served as General Manager, North America. He brings more than 25 years of industry experience in developing and commercializing innovative therapies. Prior to OvaScience, Mr. Villalba was Chief Business Officer at Evofem, a startup company that specializes in women’s health, where he led portfolio development and managed strategic partnerships. Prior to Evofem, Mr. Villalba served as Global Vice President of Sales at Auxogyn, a TPG Texas Pacific Group and Kliener Perkins company that specializes in in vitro fertilization products, where he secured a key strategic partnership with Merck Serono for European commercialization. Earlier in his career he worked at Conceptus and served as the General Manager of Europe. He was part of the team that completed the $1.1 billion sale of the company to Bayer AG.
Mr. Villalba earned a B.A. in Business Management at Menlo College.